fda approved glp-1 gip medications 2025 Manufacturers Must Adapt to Growing and GIP/GLP-1 RA Markets GLP-1 Receptor Agonists – From

Do not discontinue Wegovy without medical advice, as your clinician may suggest dose adjustments, additional investigations, or alternative management strategies

With GLP1 medications like Wegovy or Zepbound, patients often lose 1522% of their body weight over timeand more importantly, they keep it off with long-term medical support

ELIXA [51] stato uno studio randomizzato, in doppio cieco, a gruppi paralleli disegnato per valutare limpatto di lixisenatide sul rischio cardiovascolare rispetto a placebo su una popolazione di 6068 soggetti adulti diabetici con recente episodio di sindrome coronarica acuta

In other words, barely 1 in 7 patients remains on GLP-1 therapy after two years , despite obesity being a chronic condition requiring long-term treatment